Skip to main content
Funded Studies

Christopher U. Missling, PhD, MBA

President at Anavex Life Sciences Corp.

Location: New York, NY United States

Christopher U. Missling, PhD, president and CEO of Anavex, has more than 20 years of health care industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the chief financial officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the health care practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of health care investment banking at Brimberg & Co. in New York.

Dr. Missling has an MS and PhD from the University of Munich in chemistry and an MBA from Northwestern University Kellogg School of Management.

Associated Grants

  • Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease


  • Neurorestorative Effects of a Sigma-1 Receptor Agonist in a Model of Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.